Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS-L1023 with Ranibizumab in Wet-AMD
NCT03725501Phase 2Completed
- Sponsor
- AngioLab, Inc.
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALS-L1023 in exudative macular degeneration, sponsored by AngioLab, Inc.. Started Dec 2018; status: completed.
02
Drugs
ALS-L1023
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03725501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725501.